Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction
The freeze-thaw cycle can fracture the peptides delicate structure, denaturing it and reducing its efficacy
Even after reaching the target weight, the patient will still need to be on a maintenance dose to ensure they dont regain the weight
a GP can review currently licensed options and signpost eligible patients to clinical trials
The most commonly reported adverse effects in the Phase 2 trial included: Nausea the most prevalent side effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst contributing to weight loss, can be uncomfortable) Eructation (belching) Injection-site reactions (such as redness, bruising, or discomfort at the injection site) These effects are typically mild to moderate in severity and tend to be most pronounced during the first few weeks of treatment or following each dose increase
Its appeal extends beyond the peptides trend in the fitness and bodybuilding industries largely due to the mainstream popularity of GLP1 agonist weight loss drugs like Ozempic
